High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
WNT5A
prostate cancer
risk
stromal tissue
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
01
02
2021
accepted:
25
02
2021
pubmed:
28
2
2021
medline:
7
1
2022
entrez:
27
2
2021
Statut:
ppublish
Résumé
Prostate cancer (PCa) is a major cause of cancer-related death in men. Tumor-derived protein derived from Wnt5A gene (WNT5A) plays an important role in primary and metastatic PCa. Surrounding stroma cells also produce WNT5A, which may modulate the biology of PCa. Here, we assessed the role of stroma-derived WNT5A (stWNT5A) in primary PCa. A tissue microarray of samples obtained from 400 patients who underwent radical prostatectomy and control samples from 41 patients with benign prostate hyperplasia (BPH) was immunohistochemically assessed for expression of stWNT5A. The cores were scored for staining intensity: 0 (no staining), 1 (weak), 2 (moderate), or 3 (strong) and the stained stromal surface area: 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), or 4 (76-100%). Gleason Score (GS) and TNM-stage were assessed by stratifying the cohort into high-risk (≥ pT3, pN1, GS ≥ 8) and non-high-risk patients. Ki67 and TUNEL assays were performed to assess proliferation and apoptosis. Expression of stWNT5A in BPH and tumor-free control samples was 1.2-fold higher compared to tumor samples (P < 0.001). Non-high-risk patients had a higher stWNT5A score than high-risk patients (P < 0.05). stWNT5A expression was not correlated with overall and cancer-specific survival. Proliferation (r
Identifiants
pubmed: 33639039
doi: 10.1002/2211-5463.13131
pmc: PMC8016115
doi:
Substances chimiques
Biomarkers, Tumor
0
WNT5A protein, human
0
Wnt-5a Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186-1194Informations de copyright
© 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Aging (Albany NY). 2019 Jun 13;11(11):3414-3415
pubmed: 31195369
PLoS One. 2011;6(10):e26539
pubmed: 22039506
Oncotarget. 2018 Jun 5;9(43):27293-27304
pubmed: 29930766
Pharmacol Ther. 2013 Apr;138(1):66-83
pubmed: 23328704
Cancer Res. 2006 Nov 1;66(21):10439-48
pubmed: 17079465
Int J Mol Sci. 2018 Apr 09;19(4):
pubmed: 29642534
Blood. 2013 Jun 20;121(25):5045-54
pubmed: 23660959
Cancer Med. 2012 Aug;1(1):96-104
pubmed: 23342259
Oncogene. 2005 Feb 10;24(7):1277-83
pubmed: 15592517
Nat Med. 2012 Feb 19;18(3):405-12
pubmed: 22344299
Clin Cancer Res. 2008 Sep 15;14(18):5825-32
pubmed: 18794093
Mol Med Rep. 2013 Nov;8(5):1486-92
pubmed: 24064566
Cancer Cell. 2003 Nov;4(5):349-60
pubmed: 14667502
Cancer Res. 2005 Oct 15;65(20):9142-6
pubmed: 16230369
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Development. 1999 Mar;126(6):1211-23
pubmed: 10021340
Diagn Pathol. 2006 Apr 03;1:4
pubmed: 16759347
Hum Pathol. 2000 May;31(5):578-83
pubmed: 10836297
J Bone Miner Res. 2015 Mar;30(3):471-80
pubmed: 25224731
Clin Cancer Res. 2008 Jan 1;14(1):55-61
pubmed: 18172252
J Clin Oncol. 2005 Dec 1;23(34):8765-73
pubmed: 16314637
Genes Cells. 2003 Jul;8(7):645-54
pubmed: 12839624
Oncogene. 1999 Dec 20;18(55):7860-72
pubmed: 10630639
J Exp Med. 2019 Feb 4;216(2):428-449
pubmed: 30593464
J Cancer. 2019 Oct 15;10(24):5915-5925
pubmed: 31762801
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15436-41
pubmed: 17881570
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Trends Genet. 2013 Sep;29(9):545-53
pubmed: 23846023
Anticancer Res. 2005 Mar-Apr;25(2A):731-4
pubmed: 15868903
Development. 2009 Oct;136(19):3205-14
pubmed: 19736321